Nakata B, Chung K H, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue T, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M
First Department of Surgery, Osaka City University Medical School, Osaka, Japan.
Surg Today. 1998;28(6):595-8. doi: 10.1007/s005950050190.
This study was performed to evaluate p53 overexpression as a predictor of the response to chemotherapy of patients with gastric cancer. The subjects comprised 20 patients with Stage IV gastric cancer and three with locally recurrent lesions, all of whom were treated with 5-fluorouracil (5-FU) plus cisplatin (CDDP) for 4 weeks. Of the total 23 patients there were 10 responders; 2 showing complete response (CR) and 8, partial response (PR). Specimens obtained by endoscopic biopsy were immunohistochemically stained using anti-p53 protein and bcl-2 protein antibody. Of the 10 responders, 7 demonstrated negative p53 staining, and of the 13 nonresponders, 11 demonstrated positive p53 staining (P = 0.013). Tissue from 3 of the responders and 7 of the nonresponders that stained for bcl-2 were positive prior to chemotherapy; however, there was no association between bcl-2 staining and chemotherapeutic effect. In conclusion, immunohistochemical identification of p53 in pretreatment tissue may represent a useful predictor for chemotherapeutic outcome in patients with gastric cancer.
本研究旨在评估p53过表达作为胃癌患者化疗反应预测指标的价值。研究对象包括20例IV期胃癌患者和3例局部复发病灶患者，所有患者均接受5-氟尿嘧啶（5-FU）加顺铂（CDDP）治疗4周。23例患者中，有10例有反应；2例完全缓解（CR），8例部分缓解（PR）。通过内镜活检获取的标本用抗p53蛋白和bcl-2蛋白抗体进行免疫组织化学染色。10例有反应者中，7例p53染色阴性；13例无反应者中，11例p53染色阳性（P = 0.013）。3例有反应者和7例无反应者的组织在化疗前bcl-2染色呈阳性；然而，bcl-2染色与化疗效果之间无关联。总之，预处理组织中p53的免疫组织化学鉴定可能是胃癌患者化疗结果的一个有用预测指标。
